Loading…
AURO-TOFACITINIB is a brand name for Tofacitinib, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: 09/2024 1.1 INDICATIONS, Pediatrics 09/2024 4 DOSAGE AND ADMINSTRATION, 4.2 Recommended Dose and Dosage Adjustment 09/2024 7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism 09/2024 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic 09/2024 7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics 09/2024 1 INDICATIONS,…
Verbatim from this product's HC label. Tap a section to expand.
2 Breastfeeding 03/2026 Table of Contents Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed. Recent Major Label Changes .................................................................................................
2 Table of Contents ............................................................................................................... 2 Part 1: Healthcare Professional Information ......................................................................
5 1. Indications ..................................................................................................................... 1 Pediatrics ...................................................................................................................
2 Geriatrics.................................................................................................................... 6 2. Contraindications ...........................................................................................................
6 3. Serious Warnings and Precautions Box .......................................................................... 6 4. Dosage and Administration ............................................................................................
1 Dosing Considerations ............................................................................................... 2 Recommended Dose and Dosage Adjustment ........................................................... 4 Administration .........................................................................................................
11 5. Overdose ..................................................................................................................... 11 6. Dosage Forms, Strengths, Composition, and Packaging ................................................
11 Auro-Tofacitinib Product Monograph Page 3 of 93 Protected B / Protégé B 7. Warnings and Precautions ........................................................................................ 12 General ..........................................................................................................................
12 Carcinogenesis and Genotoxicity ................................................................................... 12 Cardiovascular ...............................................................................................................
2 Breastfeeding 03/2026 Table of Contents Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed. Recent Major Label Changes .................................................................................................
2 Table of Contents ............................................................................................................... 2 Part 1: Healthcare Professional Information ......................................................................
5 1. Indications ..................................................................................................................... 1 Pediatrics ...................................................................................................................
2 Geriatrics.................................................................................................................... 6 2. Contraindications ...........................................................................................................
6 3. Serious Warnings and Precautions Box .......................................................................... 6 4. Dosage and Administration ............................................................................................
1 Dosing Considerations ............................................................................................... 2 Recommended Dose and Dosage Adjustment ........................................................... 4 Administration .........................................................................................................
11 5. Overdose ..................................................................................................................... 11 6. Dosage Forms, Strengths, Composition, and Packaging ................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Tofacitinib in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
13 Driving and Operating Machinery .................................................................................. 14 Endocrine and Metabolism ............................................................................................
14 Gastrointestinal ............................................................................................................. 15 Hematologic...................................................................................................................
15 Hepatic/Biliary/Pancreatic ............................................................................................. 16 Immune .........................................................................................................................
17 Monitoring and Laboratory Tests ................................................................................... 19 Musculoskeletal .............................................................................................................
20 Renal .............................................................................................................................. 20 Reproductive Health ......................................................................................................
20 Respiratory .................................................................................................................... 1 Special Populations ..................................................................................................
1 Pregnancy ............................................................................................................. 2 Breastfeeding ........................................................................................................
3 Pediatrics .............................................................................................................. 4 Geriatrics...............................................................................................................
5 Asian Patients ....................................................................................................... 21 8. Adverse Reactions........................................................................................................
1 Adverse Reaction Overview ..................................................................................... 2 Clinical Trial Adverse Reactions................................................................................ 23 Rheumatoid Arthritis .....................................................................................................
23 Psoriatic Arthritis ........................................................................................................... 31 Ankylosing Spondylitis ...................................................................................................
31 Active Juvenile Idiopathic Arthritis ................................................................................. 32 Ulcerative Colitis ............................................................................................................
3 Less Common Clinical Trial Adverse […]
11 Auro-Tofacitinib Product Monograph Page 3 of 93 Protected B / Protégé B 7. Warnings and Precautions ........................................................................................ 12 General ..........................................................................................................................
12 Carcinogenesis and Genotoxicity ................................................................................... 12 Cardiovascular ...............................................................................................................
13 Driving and Operating Machinery .................................................................................. 14 Endocrine and Metabolism ............................................................................................
14 Gastrointestinal ............................................................................................................. 15 Hematologic...................................................................................................................
15 Hepatic/Biliary/Pancreatic ............................................................................................. 16 Immune .........................................................................................................................
17 Monitoring and Laboratory Tests ................................................................................... 19 Musculoskeletal .............................................................................................................
20 Renal .............................................................................................................................. 20 Reproductive Health ......................................................................................................
20 Respiratory .................................................................................................................... 1 Special Populations ..................................................................................................
1 Pregnancy ............................................................................................................. 2 Breastfeeding ........................................................................................................
3 Pediatrics .............................................................................................................. 4 Geriatrics...............................................................................................................
5 Asian Patients ....................................................................................................... 21 8. Adverse Reactions........................................................................................................
1 Adverse Reaction Overview ..................................................................................... 2 Clinical Trial Adverse Reactions................................................................................ 23 Rheumatoid Arthritis .....................................................................................................
23 Psoriatic Arthritis ........................................................................................................... 31 Ankylosing Spondylitis ...................................................................................................
31 Active Juvenile Idiopathic Arthritis ................................................................................. 32 […]